Who are SCYNEXIS, Inc.'s main suppliers?

SCYNEXIS, Inc. (SCYX) key suppliers include: POXEL, Merck & Co., Inc., Merck & Co., Inc.. View the full supplier network at chainsifter.com/chain/SCYX.

Who are SCYNEXIS, Inc.'s major customers?

SCYNEXIS, Inc. (SCYX) key customers include: GSK plc, GSK plc, Merck & Co., Inc., Merck & Co., Inc.. View the full customer network at chainsifter.com/chain/SCYX.

What sector is SCYNEXIS, Inc. in?

SCYNEXIS, Inc. (SCYX) operates in the general sector. ChainSifter tracks its verified supply chain relationships including suppliers, customers, and strategic partners.

SCYNEXIS, Inc. Suppliers, Customers & Supply Chain (SCYX)

3Suppliers

4Customers

3Debt Items

20Related Chains

Source-Backed Evidence Depth

SCYNEXIS, Inc. (SCYX) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.

11Total relationships

4Distinct source URLs

7High confidence

0.835Average confidence

2026-10-28Latest database update

ChainSifter does not infer unreported suppliers, customers, ownership, acquisitions, debt exposure, revenue dependency, or future supply-chain events on this public page.

SCYNEXIS, Inc. Suppliers

Ticker	Name	Confidence	Evidence
POXEL	POXEL	90%	In connection with the Transaction, Poxel also granted to the Company an exclusive, sublicensable, perpetual and irrevocable, worldwide license under certain licensed intellectual property controlled…
MRK	Merck & Co., Inc.	72%	recall affect our ongoing Phase 3 MARIO study. The hold did not impact the completed FURI, CARES, VANQUISH and SCYNERGIA clinical studies. Our clinical stage compound, SCY-247, is not affected by the…
MRK	Merck & Co., Inc.	72%	Reciprocal relationship from MRK graph: Reciprocal relationship from SCYX graph: recall affect our ongoing Phase 3 MARIO study. The hold did not impact the completed FURI, CARES, VANQUISH and SCYNERG…

SCYNEXIS, Inc. Customers

Ticker	Name	Confidence	Evidence
GSK	GSK plc	90%	Revenue consists of license agreement revenue associated with the GSK license agreement. \| Qwen verified: Explicit mention of GSK license agreement revenue indicates GSK is customer receiving licensi…
GSK	GSK plc	90%	Reciprocal relationship from GSK graph: Reciprocal relationship from SCYX graph: Revenue consists of license agreement revenue associated with the GSK license agreement. \| Qwen verified: Explicit men…
MRK	Merck & Co., Inc.	72%	recall affect our ongoing Phase 3 MARIO study. The hold did not impact the completed FURI, CARES, VANQUISH and SCYNERGIA clinical studies. Our clinical stage compound, SCY-247, is not affected by the…
MRK	Merck & Co., Inc.	72%	Reciprocal relationship from MRK graph: Reciprocal relationship from SCYX graph: recall affect our ongoing Phase 3 MARIO study. The hold did not impact the completed FURI, CARES, VANQUISH and SCYNERG…

SCYNEXIS, Inc. Debt Obligations

Instrument	Description	Confidence	Evidence
SCYX-DEBT	Debt stack $2.1M	90%	Market cache reports total debt of $2.1M.
SCYX-DEBT-12430	Warrants outstanding: 1319807	90%	xbrl warrant detail from xbrl 2025-12-31.
SCYX-DEBT-12431	Xbrl Convertible	90%	xbrl convertible detail from xbrl 2021-12-31.

SCYNEXIS, Inc. Acquisitions

No acquisitions on recordNo completed or pending acquisitions found in our database for SCYNEXIS, Inc..

SCYNEXIS, Inc. Ownership

Holder	Name	Confidence	Evidence
SCYX-OWNER-SQUADRON-CAPITAL-MANAGEMENT-LLC	Squadron Capital Management LLC	90%	13F overlay lists Squadron Capital Management LLC as top holder; 45 tracked holders.

SCYNEXIS, Inc. Extended Supply Chain Network

Ticker	Name	Chain Index	Hops	Relationship Types
SMMT	Summit Therapeutics Inc.	100.00	2
DEO	Diageo plc	100.00	2
LEGN	Legend Biotech Corporation	100.00	2
MRK	Merck & Co., Inc.	100.00	1	['customer', 'supplier']
CTNM	Contineum Therapeutics, Inc.	100.00	2
BCAX	Bicara Therapeutics Inc.	100.00	2
GSK	GSK plc	100.00	1	['customer']
PCVX	Vaxcyte, Inc.	100.00	2
LIXT	Lixte Biotechnology Holdings, Inc.	100.00	2
BDRX	Biodexa Pharmaceuticals Plc	100.00	2
AVIR	Atea Pharmaceuticals, Inc.	50.00	2
CORT	Corcept Therapeutics Incorporated	50.00	2
CHRS	Coherus Oncology, Inc.	50.00	2
DYN	Dyne Therapeutics, Inc.	50.00	2
EDSA	Edesa Biotech, Inc.	50.00	2
DKS	DICK'S Sporting Goods, Inc.	50.00	2
AZN	AstraZeneca PLC	50.00	2
BBVA	Banco Bilbao Vizcaya Argentaria, S.A.	50.00	2
CBIH	Cannabis Bioscience International Holdings, Inc.	50.00	2
REGN	Regeneron Pharmaceuticals, Inc.	50.00	2

SCYNEXIS, Inc. Supply Chain